# Recombinant Interferon Alfa-2b in Treating Patients With Melanoma

> **NCT01460875** · NA · COMPLETED · sponsor: **William Carson** · enrollment: 34 (actual)

## Conditions studied

- Stage IA Skin Melanoma
- Stage IB Skin Melanoma
- Stage IIA Skin Melanoma
- Stage IIB Skin Melanoma
- Stage IIC Skin Melanoma
- Stage IIIA Skin Melanoma
- Stage IIIB Skin Melanoma
- Stage IIIC Skin Melanoma
- Stage IV Skin Melanoma

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa-2b
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01460875
- **Lead sponsor:** William Carson
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-22
- **Primary completion:** 2014-01-05
- **Final completion:** 2014-01-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2018-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01460875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01460875, "Recombinant Interferon Alfa-2b in Treating Patients With Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01460875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*